This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ADMA Biologics Completes Merger And Closes $17.5 Million Private Placement

ADMA Biologics, Inc. (“ADMA”), a clinical stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today announced the completion of a reverse merger with R&R Acquisition VI, Inc. (“R&R VI”), a public reporting company. The transaction was completed by the merger of a wholly-owned subsidiary of R&R VI with ADMA, with ADMA remaining as the surviving company and as a wholly-owned operating subsidiary of R&R VI. R&R VI was renamed ADMA Biologics, Inc. following completion of the merger. The resulting public company will implement the business plan of ADMA.

In addition, in conjunction with the merger, ADMA announced that it raised approximately $17.5 million through a private placement of 1,828,128 shares of Common Stock to institutional investors for $9.60 per share. Burrill & Company is the lead investor in the private placement, which also included significant participation from Aisling Capital and ADMA’s founders. Proceeds from the financing will support ADMA’s pivotal Phase III clinical trial for its lead product candidate, RI-001, in order to gain FDA approval of RI-001 as an intravenous immune globulin (“IGIV”) for the treatment of patients with Primary Immunodeficiency Disease (“PIDD”).

“We are very pleased that Burrill & Company is joining us to lead this round of financing for ADMA,” said Steve Elms, Managing Partner at Aisling Capital and Chairman of the Board of ADMA Biologics. “It is a strong sign of support for ADMA’s important work developing potentially lifesaving therapies for immunocompromised patients. They clearly share our confidence in ADMA’s RI-001 and in its upcoming Phase III clinical trial.”

“It’s not often that we have an opportunity to invest in a late-stage asset like ADMA’s RI-001 and in a company like ADMA,” said Bryant Fong, Managing Director at Burrill & Company. “From both a clinical development perspective and from a potential patient benefit perspective, we see a very compelling new product candidate that addresses an area of clinical unmet need, and we believe the ADMA management team is well-equipped to bring it to commercial success.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs